U.S. internet healthcare company Hims & Hers Health (HIMS.US) surged over 40% on Monday, and continued to rise 2.3% in pre-market trading today, reaching $22.67.

On the news front, Novo Nordisk announced that it will sell its flagship weight-loss drugs to U.S. consumers through the Hims platform and will simultaneously withdraw the patent infringement lawsuit filed last month. According to the agreement, the Hims platform will provide U.S. consumers with Ozempic and Wegovy injections as well as Wegovy oral tablets at Novo Nordisk's out-of-pocket prices. Previously, Novo Nordisk had significantly reduced the monthly fee for its weight-loss drugs from about $1,000 to a range of $149 to $299. (Gelonghui)